GlassScriptPhysician profile
Melody Kneeland
NPI 1871655431
$1,342.03
in general payments reported to CMS, 2019-2025
28 companies · $594 in 2025
The $594 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.81 · 2020: $24.76 · 2021: $23.44 · 2022: $118 · 2023: $161 · 2024: $408 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $177.02 | 2022-2025 | Veozah |
| Novo Nordisk INC | $134.44 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Dexcom, INC. | $126.40 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $125.39 | 2023-2025 | |
| Lilly USA, LLC | $118.78 | 2024-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $106.78 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $67.41 | 2022-2024 | Krystexxa |
| Pfizer INC. | $65.61 | 2025 | |
| Exact Sciences Corporation | $60.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.14 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $31.06 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.27 | 2025 | Xifaxan |
| Ascensia Diabetes Care US INC. | $24.81 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.61 | 2022 | |
| Medtronic, INC. | $19.49 | 2024 | Intellis Adaptivestim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $19.11 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biohaven Pharmaceutical Holding Company LTD. | $18.85 | 2022 | |
| Antares Pharma, INC. | $17.33 | 2025 | Xyosted |
| Inspire Medical Systems, INC. | $16.70 | 2025 | Inspire |
| Shield Therapeutics INC | $15.88 | 2025 | |
| Merck Sharp & Dohme LLC | $15.14 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $15.08 | 2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.62 | 2025 | Jardiance |
| Halozyme INC | $14.09 | 2023 | |
| Sanofi Pasteur INC. | $12.89 | 2020 | |
| Shire North American Group INC | $12.81 | 2019 | |
| Gt Medical Technologies, INC | $12.41 | 2022 | |
| Glaxosmithkline, LLC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Kneeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.